Atsena Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Atsena Therapeutics's estimated annual revenue is currently $3.2M per year.
- Atsena Therapeutics's estimated revenue per employee is $77,500
- Atsena Therapeutics's total funding is $63.2M.
Employee Data
- Atsena Therapeutics has 41 Employees.
- Atsena Therapeutics grew their employee count by -16% last year.
Atsena Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Regulatory | Reveal Email/Phone |
2 | VP, CMC | Reveal Email/Phone |
3 | SVP CMC | Reveal Email/Phone |
4 | VP Translational Research | Reveal Email/Phone |
5 | Chief Medical Officer | Reveal Email/Phone |
6 | Founder and Chief Technology Officer | Reveal Email/Phone |
7 | Associate Director Quality Operations | Reveal Email/Phone |
8 | Senior Medical Director | Reveal Email/Phone |
9 | Director, Patient Advocacy and Medical Affairs | Reveal Email/Phone |
10 | Founder and Chief Scientific Officer | Reveal Email/Phone |
Atsena Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Atsena Therapeutics?
Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. We have an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. Our additional pipeline of leading preclinical assets is powered by an adeno-associated virus (AAV) technology platform tailored to overcome significant hurdles presented by inherited retinal disease. Founded by ocular gene therapy pioneers Dr. Shannon Boye and Sanford Boye, Atsena has strong ties with the University of Florida. Our offices are located in Durham, NC and Boston, MA, environments rich in gene therapy expertise.
keywords:N/A
$63.2M
Total Funding
41
Number of Employees
$3.2M
Revenue (est)
-16%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Atsena Therapeutics News
Atsena Therapeutics, a Durham, N.C. and Boston, MA-based clinical-stage gene therapy company, closed a $55m Series A financing. The round was led by Sofinnova Investments with participation from additional new investors Abingworth and Lightstone Ventures and founding investors Hatteras Venture ...
Atsena Therapeutics, a Durham, N.C. and Boston, MA-based clinical-stage gene therapy company, closed a $55m Series A financing. The round was led by Sofinnova Investments with participation from additional new investors Abingworth and Lightstone Ventures and founding investors Hatteras Venture ...
University of Florida (UF) spinout Atsena Therapeutics has closed a $55 million financing that will help take its gene therapy for a common cause of blindness in children into pivotal trials. Sponsored by Agilent Technologies How would you like to win free bench space at Lab Central for one sc ...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.1M | 41 | 0% | N/A |
#2 | $8.1M | 41 | 5% | N/A |
#3 | $7.7M | 41 | 41% | N/A |
#4 | $5.7M | 41 | -27% | N/A |
#5 | $7.5M | 41 | 17% | N/A |